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Glycoproteins present problems for structural analysis since they often have
to be glycosylated in order to fold correctly and because their chemical and
conformational heterogeneity generally inhibits crystallization. It is shown that
the  -mannosidase I inhibitor kifunensine, which has previously been used for
the purpose of glycoprotein crystallization in short-term (3–5 d) cultures, is
apparently stable enough to be used to produce highly endoglycosidase H-
sensitive glycoprotein in long-term (3–4 week) cultures of stably transfected
Chinese hamster ovary (CHO) cells. Matrix-assisted laser desorption/ionization
time-of-ﬂight mass spectrometry-based analysis of the extracellular region of
the cytotoxic T-lymphocyte antigen 4 (CTLA-4; CD152) homodimer expressed
in long-term CHO cell cultures in the presence of kifunensine revealed that
the inhibitor restricted CTLA-4 glycan processing to Man9GlcNAc2 and
Man5GlcNAc2 structures. Complex-type glycans were undetectable, suggesting
that the inhibitor was active for the entire duration of the cultures. Endo-
glycosidase treatment of the homodimer yielded protein that readily formed
orthorhombic crystals with unit-cell parameters a = 43.9, b = 51.5, c = 102.9 A ˚
and space group P212121 that diffracted to Bragg spacings of 1.8 A ˚ . The results
indicate that kifunensine will be effective in most, if not all, transient and long-
term mammalian cell-based expression systems.
1. Introduction
Protein glycosylation generally inhibits the crystallization of glyco-
proteins, but is often required for their correct folding (reviewed by
Davis & Crispin, 2011). Our initial solutions to the glycosylation
problem involved the use of long-term Chinese hamster ovary (CHO)
cell-based expression systems in which folding and initial glycosyl-
ation of the glycoprotein were allowed to proceed normally but the
subsequent processing of the N-linked glycans was restricted in a way
that allowed their enzymatic removal from the puriﬁed glycoprotein
with endoglycosidase H (Endo H; Davis et al., 1993, 1995; Butters et
al., 1999). Endo H cleaves between the GlcNAc residues in the di-
N-acetylchitobiose core of oligomannose-type and hybrid-type
N-glycans, leaving single  -GlcNAc residues at each glycosylation
sequon. To implement these methods in a high-throughput (i.e.
structural-genomics-based) setting, we explored the use of glycosyl-
ation processing inhibitors in cells that can be transiently transfected,
such as human embryonic kidney (HEK) 293T cells (Chang et al.,
2007). This required the use of inhibitors that are likely to circumvent
the endomannosidase-based shunt pathway present in HEK 293T
cells, which currently provide the benchmark for high-level transient
mammalian protein expression (Chang et al., 2007). We found that
glycoproteins expressed in 3–5 d cultures of HEK 293T cells in the
presence of relatively low levels of the  -mannosidase I inhibitor
kifunensine exhibited high levels of sensitivity to Endo H without
compromising overall expression yields. Although the general effects
of kifunensine and other alkaloid-like processing inhibitors have
been very well established (Elbein, 1991), for the most part this
information has come from biochemical analyses of relatively
short-term cultures. Following culture for 12 d in the presence ofkifunensine, recombinant human immunoglobulin expressed in CHO
cells was shown to contain ‘mainly’ oligomannose-type N-glycans
(van Berkel et al., 2010), but the ability of kifunensine to efﬁciently
inhibit glycan processing for periods beyond this was unknown.
Not all proteins of structural interest are amenable to high-
throughput expression in transient cultures and our previous work
with long-term stable expression systems involved the use of difﬁcult-
to-transfect cells or hard-to-obtain glycosylation inhibitors (Davis &
Crispin, 2011). The apo form of the homodimeric extracellular region
of human cytotoxic T-lymphocyte antigen 4 (CTLA-4; CD152), the
product of the CTLA4 gene and a critical modulator of human
immune responses (Fife & Bluestone, 2008), refolds incorrectly from
bacterial inclusion bodies (Sonnen et al., 2010) and is usually
expressed as an immunoglobulin Fc fusion protein to effect faithful
dimerization, which compromises yields. We show that kifunensine is
an effective inhibitor of N-glycan processing in long-term (3–4 week)
cultures of CHO cells and use this method to obtain high-quality
crystals of the apo CTLA-4 homodimer. Our results suggest that
kifunensine will be effective in most, if not all, short-term and long-
term mammalian cell expression systems. Analysis of the crystals of
the CTLA-4 homodimer has provided key insights into the structural
basis of triggering of this important receptor (Yu et al., 2010).
2. Methods
2.1. Protein expression
Chimeric cDNA encoding, in the following order, residues 1–161 of
the extracellular (ex) region of human CTLA-4, including the signal
peptide sequence, a thrombin cleavage site, the heavy-chain constant
domains 2 and 3 of murine IgG1 (Fc) and a C-terminal Lys-His6 tag
was cloned into the pEE14 expression vector (Bebbington & Hent-
schell, 1987; Davis et al., 1990). The expression vector encoding the
chimeric CTLA-4-Fc-Lys-His6 construct (abbreviated to CTLA-
4exFc) was then transfected into CHO-K1 cells followed by clone
selection with 25 mM methionine sulfoximine. Among the surviving
clones, one expressed CTLA-4exFc at a level of approximately
15 mg l
 1 and this was used for protein production in large-scale
cultures (Cell Factories; Nunc, Roskilde, Denmark) in the presence
of 10 mM kifunensine (Toronto Research Chemicals, North York,
Ontario, Canada) for up to three weeks following the addition of
2m M sodium butyrate to boost expression.
2.2. Protein purification and crystallization
The CTLA-4exFc was harvested after 3–4 weeks of culture and the
protein was extracted by metal-chelate chromatography using Ni–
NTA agarose (Qiagen, West Sussex, England). The CTLA-4exFc was
eluted from the Ni–NTA agarose with 250 mM imidazole in 20 mM
Tris–HCl, 0.5 M NaCl pH 8.0 and further puriﬁed by size-exclusion
chromatography (Superdex 200 HR 10/30 column; GE Healthcare,
Amersham, England). Removal ofthe Fc from CTLA-4exFc, yielding
residues 1–126 of the mature CTLA-4 polypeptide followed by the
Leu-Val-Pro-Arg sequence from the cleaved thrombin site, was
achieved by treating the protein with thrombin in 10 mM HEPES,
150 mM NaCl pH 7.4 at room temperature for 16 h. Non-Ni–NTA-
agarose-bound (i.e. cleaved) CTLA-4ex homodimer was buffer-
exchanged to 10 mM HEPES, 150 mM NaCl pH 7.4 and deglycosyl-
ated with Endo Hf (New England Biolabs, Hitchin, England) at room
temperature for 3 h. The deglycosylated Endo Hf-treated CTLA-4ex
homodimer was puriﬁed by lectin-afﬁnity chromatography and gel
ﬁltration as previously described (Davis et al., 1995).
Initial conditions for CTLA-4ex homodimer crystallization were
screened using a sparse-matrix crystallization screening kit at 295 K
(Hampton Research, Laguna Niguel, California, USA). Droplets
(100 nl) of protein at 14.5 mg ml
 1 in 10 mM HEPES, 150 mM NaCl
pH 7.4 were mixed with 100 nl reservoir solution and set up in 96-well
plates as described previously (Walter et al., 2005). Following freezing
of the crystals in glycerol/precipitant, diffraction data were collected
on beamline I04 of the Diamond Light Source, England. Data were
processed and scaled with the HKL suite (Otwinowski & Minor,
1997).
2.3. Glycan analysis and structural assignment
Glycans were released using protein N-glycanase (PNGase) F
(Ku ¨ster et al., 1997) for analysis by positive-ion matrix-assisted laser
desorption/ionization (MALDI) time-of-ﬂight (TOF) mass spectro-
metry (MS) and negative-ion electrospray ionization (ESI) MS.
Bands from Coomassie Blue-stained SDS–PAGE gels containing
approximately 10 mg target glycoprotein were excised and eluted with
alternating water/acetonitrile washes, dried and rehydrated with 30 ml
30 mM NaHCO3 pH 7.0 containing 100 units ml
 1 of PNGase F
(Prozyme, San Leandro, California, USA). The released N-linked
glycans were eluted and cleaned with a Naﬁon 117 membrane
(Bo ¨rnsen et al., 1995) prior to mass spectrometry. Positive-ion
MALDI–TOF mass spectra were recorded with a Shimazu AXIMA
TOF
2 MALDI TOF/TOF mass spectrometer (Shimadzu-Kratos,
Manchester, England) ﬁtted with delayed extraction and a nitrogen
laser (337 nm). Samples were prepared by adding 0.5 mlo fa n
aqueous solution of the glycans to the matrix solution [0.3 mlo fa
saturated solution of recrystallized 2,5-dihydroxybenzoic acid in
1:1(v:v) acetonitrile:water containing a trace of sodium chloride] on
the stainless-steel target plate and allowing it to dry at room
temperature, followed by recrystallization from ethanol.
MALDI mass spectra of the glycans from the CTLA-4 glycoforms
revealed compositional information by the identiﬁcation of
(M + Na)
+ ions, whilst the structural assignment of the ions was
achieved by negative-ion ESI MS using a Waters quadrupole time-of-
ﬂight (Q-Tof) Ultima Global instrument (Waters MS Technologies,
Manchester, England). For ESI MS, samples in 1:1(v:v) methanol:
water were infused through Proxeon nanospray capillaries (Proxeon
Biosystems, Odense, Denmark). The ion-source conditions were as
follows: temperature, 393 K; nitrogen ﬂow, 50 l h
 1; infusion needle
potential, 1.1 kV; cone voltage, 100 V; RF-1 voltage, 180 V. For
MS/MS data acquisition, the parent ion was selected at low resolution
to allow transmission of isotope peaks and was fragmented with
argon at a pressure of 100 Pa. Instrument control, data acquisition
and processing were performed with MassLynx software v.4.1
(Waters). Fragmentation spectra were analyzed as described
previously (Harvey, 2005a,b,c,d; Harvey et al., 2008). The nomen-
clature used follows that of Domon & Costello (1988) and is distinct
from the established labels of the branches of the oligomannose-type
glycans D1–D3.
3. Results
3.1. Expression and crystallization of CTLA-4ex from CHO-K1 cells
cultured with kifunensine
CTLA-4ex homodimer was prepared from the supernatants of
long-term (3–4 week) cultures of CHO-K1 cells grown in the
presence of kifunensine. Preliminary optimization utilizing a chimeric
Fc-fusion protein containing the extracellular region of the
programmed death 1 (PD-1) protein indicated that the lowest
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sensitivity following expression in CHO-K1 cells was 10 mM (data not
shown). To compare the sensitivity of CTLA-4ex generated in the
presence of kifunensine versus other approaches, we also prepared
CTLA-4ex from untreated CHO-K1 cells, from CHO-K1 cells treated
with the  -glucosidase I inhibitor N-butyldeoxynojirimycin (NB-
DNJ; Davis et al., 1995), from mutant CHO-derived Lec3.2.8.1 cells
whose ability to process glycans beyond the Man5GlcNAc2 stage is
severely limited (Davis et al., 1993) and from Lec3.2.8.1 cells treated
with NB-DNJ (Butters et al., 1999). Whereas the CHO-K1 cell-
derived CTLA-4ex was completely resistant to Endo H, all other
forms exhibited varying degrees of sensitivity, with protein expressed
in Lec3.2.8.1 cells and in CHO-K1 cells, both with NB-DNJ,
exhibiting the greatest and least sensitivity, respectively (Fig. 1a).
CTLA-4ex expressed in the presence of kifunensine, and in
Lec3.2.8.1 cells only, exhibited similar intermediate levels of sensi-
tivity. The sensitivity of CTLA-4ex expressed in CHO-K1 cells in the
presence of kifunensine during 3–4 week cultures was comparable to
that observed for proteins expressed in short-term (i.e. 2–3 d)
cultures of HEK 293T cells in the presence of the inhibitor (Chang et
al., 2007).
Crystals of deglycosylated lectin-puriﬁed CTLA-4ex grew in a
variety of conditions: (i) 25%(w/v) polyethylene glycol 1500 in 0.1 M
sodium propionate/sodium cacodylate/Bis-Tris propane buffer pH
6.0; (ii) 0.2 M sodium dihydrogen phosphate, 25%(w/v) polyethylene
glycol 3350; (iii) 30%(w/v) polyethylene glycol 6000, 0.1 M citrate pH
5.0 and (iv) 0.2 M ammonium acetate, 25%(w/v) polyethylene glycol
1500, 0.1 M Bis-Tris pH 5.5. Examples of crystals are shown in
Figs. 1(b) and 1(c). The best diffraction observed was to 1.8 A ˚ reso-
lution, but the diffraction had a high background and contained a
good number of split spots with high mosaicity. However, diffraction
was improved by scaling up the drop volume from 200 nl to 2 ml and
by using the traditional sitting-drop vapour-diffusion method (Harlos
et al., 1992). The self-rotation function and a Harker section of the
native Patterson function clearly established that the space group is
P212121 (data not shown). Data-collection and processing statistics
are given in Table 1.
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Figure 1
Deglycosylation and crystallization of the apo CTLA-4 homodimer. (a) Coomassie-stained SDS–polyacrylamide gel run under reducing conditions showing undigested ( )
and Endo H-digested (+) CTLA-4ex expressed in wild-type and mutant CHO cells with and without glycan-processing inhibitors. Samples in the left and right lanes marked
with (+) were Endo H-digested for 1 and 3 h, respectively, in order to conﬁrm that after 1 h the reaction had proceeded to completion. Sample 1, CHO-K1 cells only; sample
2, CHO-K1 cells with 1.5 mM NB-DNJ; sample 3, CHO-K1 cells with 10 mM kifunensine; sample 4, CHO Lec3.2.8.1 cells only; sample 5, CHO Lec3.2.8.1 cells with 0.5 mM
NB-DNJ. In (b) crystals were grown in 25%(w/v) polyethylene glycol 1500 in 0.1 M sodium propionate/sodium cacodylate/Bis-Tris propane buffer pH 6.0 (Molecular
Dimensions). These crystals were  100   100   100 mm in size. The crystal shown in (c) was grown in 0.2 M ammonium acetate, 25%(w/v) polyethylene glycol 1500, 0.1 M
Bis-Tris pH 5.5 (Hampton Research). This crystal was  100   200   100 mmi ns i z e .
Table 1
Data-collection and processing statistics.
Values in parentheses are for the highest resolution shell.
No. of crystals 1
Beamline I04
Wavelength (A ˚ ) 0.9697
Detector ADSC Q315r
Crystal-to-detector distance (mm) 270
Rotation range per image ( ) 0.75
Total rotation range ( ) 264.75
Exposure time per image (s) 0.8
Resolution range (A ˚ ) 25–1.8 (2.0–1.8)
Space group P212121
Unit-cell parameters (A ˚ ) a = 43.9, b = 51.5, c = 102.9
Mosaicity ( ) 0.291
Total No. of measured intensities 211670
Unique reﬂections 22222 (5907)
Multiplicity 9.52 (8.23)
Mean I/ (I) 10.33 (3.19)
Completeness (%) 99.7 (99.4)
Rmerge (%)† 11.1 (33.8)
Rmeas or Rr.i.m. (%) 18.3 (70.8)
Overall B factor from Wilson plot (A ˚ 2) 36.803
† Rmerge =
P
hkl
P
i jIiðhklÞ h IðhklÞij=
P
hkl
P
i IiðhklÞ, where Ii(hkl)i st h eith observa-
tion of reﬂection hkl and hI(hkl)i is the weighted average intensity for all observations l
of reﬂection hkl.3.2. Effects of kifunensine on glycan processing in CHO-K1 cells
The glycans released from CTLA-4ex homodimers expressed
under the ﬁve sets of conditions were analyzed by MALDI–TOFand
ESI mass spectrometry. The MALDI mass spectrum for N-linked
glycans from CTLA-4ex from CHO-K1 cells cultured with 1.5 mM
NB-DNJ revealed a dominant peak at m/z 2067 corresponding to
Hex10HexNAc2 (Fig. 2a). This composition can be assigned to the
speciﬁc isomer Glc3Man7GlcNAc2 by the collision-induced decom-
position (CID) spectrum of the corresponding (M +C l )
  ion, which
revealed diagnostic ions for the trimannosyl 6-antennae (C3  and C3 
at m/z 503.1 and the D and D   18 ions at 647.2 and 629.2, respec-
tively) and the 3-antennae (
1,3A5 and
2,4A5 ions at m/z 707.2 and
1,3A6
and
2,4A6 at m/z 869.2) (Supplementary Fig. S1a
1). This structure is
consistent with the almost complete inhibition of processing by
 -glucosidase I achieved at 1.5 mM and matches that previously
reported for glycoproteins expressed in CHO-K1 cells with high
levels of NB-DNJ (Butters et al., 1999; Crispin et al., 2006). The
2,4A8,
B8 and
2,4A8 ions and corresponding ions in the other spectra shown
in Supplementary Fig. S1(a)
1 are diagnostic for the mannosyl-
chitobiose trisaccharide core and show no substitutions in this region
of the molecule.
For glycans derived from CHO Lec3.2.8.1 cells in the presence of
0.5 mM NB-DNJ (Fig. 2b) the dominant ion at m/z 2067.9 gave a CID
spectrum indicating Glc3Man7GlcNAc2 as above. The corresponding
spectrum of the ion at m/z 1257.6 was identical to that from a
reference sample of Man5GlcNAc2. The spectrum of the ion at m/z
1743.8 corresponding to Hex8HexNAc2 is shown in Supplementary
Fig.S1(b)
1.B 3 ,C 3 ,
0,3A7,D 18 and D ions at m/z 485, 503, 575, 629
and 647, respectively, showed the presence of the Man3-containing
6-antenna. The other four hexose residues must therefore comprise
the 3-antenna and consist of Glc1Man3. This conclusion was
supported by the ions at m/z 545, 383 and 323, which were speciﬁc to
the 3-antenna and 2   162 mass units lower than their counterparts in
the spectrum of Glc3Man7GlcNAc2.
In the MALDI–TOF spectrum for glycans from CHO-K1 cells in
the presence of 10 mM kifunensine (Fig. 2c), compounds producing
the ions at m/z 1905.7 and 1257.5 gave CID spectra showing the
normal Man9GlcNAc2 and Man5GlcNAc2 structures. The spectrum of
Man9GlcNAc2 is shown in Supplementary Fig. S1(c)
1.B 3 ,C 3 ,
0,3A7,
D   18 and D ions at m/z 809, 827, 899, 953 and 971, respectively,
conﬁrmed the Man5 structure of the 6-antenna. The corresponding
CID spectrum of the compound with the composition Hex8HexNAc2
(m/z 1743.7 in the MALDI–TOF spectrum) is shown in Supple-
mentary Fig. S1(d)
1. Its CID spectrum contained B3 ,C 3 ,
0,3A7,
D   18 and D ions at the same masses as those in the spectrum of
Man9GlcNAc2, indicating a Man5-containing 6-antenna and showing
that a mannose was missing from the 3-antenna. The isomeric D1,D3
Man8GlcNAc2 that is the normal product of the ﬁrst exomannosidase
cleavage gave the spectrum shown in Supplementary Fig. S1(e)
1.T h e
presence of one fewer mannose residue in the 6-antenna is reﬂected
by the masses of the B3 ,C 3 ,
0,3A7,D  18 and D ions, which are 162
units lower than in the spectrum of the isomer shown in Supple-
mentary Fig. S1(d)
1. Complex-type structures were undetectable
in the spectrum from kifunensine-treated cells. The MALDI–TOF
spectrum for glycans released from CTLA-4ex expressed in CHO
Lec3.2.8.1 cells (Fig. 2d) revealed the production of only
Man5GlcNAc2, whereas the spectrum for protein from untreated
CHO-K1 cells (Fig. 2e) showed complex-type glycans, explaining its
unreactivity towards Endo H.
4. Discussion
Since kifunensine targets highly conserved class I mannosidases
downstream of the endomannosidase-dependent shunt pathway, our
expectation was that it might be effective in a number of mammalian-
cell-based expression systems (Chang et al., 2007; Nettleship et al.,
2009). It was not obvious, however, that kifunensine was sufﬁciently
stable in very long-term (e.g. 3–4 week) stable cultures versus short-
term (2–3 d) transient cultures to affect the glycan processing of all
the glycoprotein produced during extended culture. However, we
succeeded in producing glycoprotein that could be very efﬁciently
deglycosylated with Endo H even from cultures kept for as long as
four weeks. The glycan analysis was notable for the complete absence
of detectable complex-type glycans in the sample prepared in the
presence of kifunensine, suggesting either that the inhibitor is stable
for the entire period of the culture or that the cells only express
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Figure 2
Positive-ion MALDI–TOF mass spectra of N-linked glycans from glycoforms of
CTLA-4ex expressed in CHO-K1 cells with 1.5 mM NB-DNJ (a), CHO Lec3.2.8.1
cells with 0.5 mM NB-DNJ (b), CHO-K1 cells with 10 mM kifunensine (c),
CHO Lec3.2.8.1 cells (d) and CHO-K1 cells (e). A trace amount of putative
Man3GlcNAc2 and Man4GlcNAc2 glycans was detected in the spectra of CHO
Lec3.2.8.1 but was obscured by contaminating peaks (not shown). Symbols used for
the structural formulae: diamonds, Gal; ﬁlled diamonds, GalNAc; ﬁlled squares,
GlcNAc; circles, Man; stars, sialic acid; diamonds with dots in, Fuc. The linkage
position is shown by the angle of the lines linking the sugar residues (vertical line, 2-
link; forward slash, 3-link; horizontal line, 4-link; back slash, 6-link), whilst the
anomericity is indicated by full lines for  -bonds and broken lines for  -bonds
(Harvey et al., 2009).
1 Supplementary material has been deposited in the IUCr electronic archive
(Reference: BW5387).protein for a brief period during which the inhibitor is active.
Analysis of the kinetics of expression of other proteins, in which the
cells secrete the heterologous gene product for the lifetime of the
culture (S. J. Davis et al., unpublished work), supports the former
possibility. Although we did not directly examine the effect of kifu-
nensine on the levels of expression of CTLA-4ex, we previously
showed that transiently transfected HEK 293T cells treated with the
inhibitor produced 30% more protein than untreated cells, presum-
ably owing to effects on ER-associated degradation (Chang et al.,
2007). At present, we have no reason to suspect that this will not also
be the case for CHO cells.
We undertook the structural analysis of unliganded CTLA-4ex in
order to determine, via comparisons with ligand-bound complexes
of CTLA-4 (Schwartz et al., 2001; Stamper et al., 2001), whether
conformational changes accompany ligand-induced triggering of the
receptor. The unusual situation arose that details of the crystal-
lization of bacterially expressed human CTLA-4ex have been
reported (Chang et al., 2000), but the structure was not subsequently
published. Similarly, Schwartz and coworkers referred in passing to
having determined the structure of the apo form of CTLA-4ex in
their study of the complex of CTLA-4 with domain 1 of B7-2, but did
not subsequently publish their observations (Schwartz et al., 2001).
We found that apo CTLA-4 monomers expressed in bacteria
according to the method of Chang et al. (2000) formed strand-
exchanged dimers during crystallization (Sonnen et al., 2010).
Mammalian cell-expressed material, on the other hand, yielded very
high-quality crystals of an apo CTLA-4 homodimer lacking the
strand exchange and is, we assume, natively folded owing to its
similarities to ligand-bound CTLA-4 (Schwartz et al., 2001; Stamper
et al., 2001). The new structure of the apo form of CTLA-4 produced
as described here conﬁrms that conformational rearrangements do
not accompany ligand binding by the CTLA-4 homodimer (Yu et al.,
2010). These observations place additional constraints on the
mechanism of signalling by receptors dependent on extrinsic tyrosine
kinases such as CTLA-4 and the T-cell receptor.
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